iRhythm Technologies Expands ZIO® Service To Include True Atrial Fibrillation Duration Reporting
SAN FRANCISCO, April 28, 2016 /PRNewswire/ -- iRhythm Technologies, Inc., a leading digital healthcare company focused on the advancement of cardiac care, announced today a significant enhancement of ZIO® Reports. The report now includes True Atrial Fibrillation (AFib) Duration, the validated amount of time an episode of AFib lasts. The availability of AFib Duration data, coupled with True AFib Burden data provided by the ZIO® Service, can facilitate management of AFib, a condition that increases a patient's chance of stroke by five times.
The duration of an AFib episode can make a significant difference in clinical management. An episode of 30 seconds in duration (sub-clinical AFib) has a different clinical relevance than an episode of six minutes or more, according to results from the 2014 ASSERT trial. Understanding True AFib Duration can support the clinical care pathway by helping the clinician determine the risk of stroke, the efficacy and use of anti-coagulants, the efficacy of cardioversion, and rate control or rhythm control. This additional enhancement makes the ZIO® Service uniquely capable of providing a comprehensive approach towards AFib diagnosis and management.
True AFib duration can only be reported if segments of a single episode interrupted by artifact in the recording are "bridged" and timed as a single episode. The new reporting output combines the precision of beat-to-beat analysis with an intelligent bridging approach to provide accurate AFib Duration reporting over a patient's entire monitoring prescription period.
"Quantifying an individual patient's AF burden as well as the frequency and duration of AF episodes is essential for us to provide tailored, maximally beneficial therapy," said Zayd Eldadah, MD, PhD, Director, Cardiac Electrophysiology, MedStar Heart and Vascular Institute. "As a provider, I rely on the enhanced ZIO Reports, which provide concise, clearly presented data, enabling me to manage my patients more effectively."
True AFib Duration reporting along with other significant enhancements to the ZIO Report will be demonstrated at a hands-on educational session at the Heart Rhythm Society's 37th Annual Scientific Sessions on May 4 from 11am – 3pm in Room 120-125 at Table #10. You can also learn more about the ZIO Service and True AFib Duration reporting at the iRhythm Technologies' booth #2330 at HRS Sessions.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital health care company focused on cardiac arrhythmia detection. The company combines wearable biosensor devices with cloud-based technology to improve how heart arrhythmias are diagnosed and managed. iRhythm's digital health technology and diagnostic support services provide clear, actionable information for physicians, and are clinically proven to enhance clinical decision making. Its flagship solution, the ZIO Service, offers a proven approach to continuous ECG monitoring for up to 14 days. The ZIO Service may enable physicians to diagnose arrhythmias earlier in the clinical pathway in order to improve patient outcomes and reduce healthcare costs. The ZIO Service has been used with over 400,000 patients at nearly 1,000 institutions across the U.S., making use of over 100 million hours of heartbeat data from continuous ECG recordings. For more information, please visit www.irhythmtech.com.
Media Contact
Aaron Murphy
[email protected]
415-229-3331
SOURCE iRhythm Technologies, Inc.
Share this article